We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Takeda Pharmaceutical Co (TAK) ADR Each Repr 0.5 Share Sponsored

Sell:$13.22 Buy:$13.23 Change: $0.09 (0.68%)
Market closed |  Prices as at close on 17 May 2024 | Switch to live prices |
Sell:$13.22
Buy:$13.23
Change: $0.09 (0.68%)
Market closed |  Prices as at close on 17 May 2024 | Switch to live prices |
Sell:$13.22
Buy:$13.23
Change: $0.09 (0.68%)
Market closed |  Prices as at close on 17 May 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Takeda Pharmaceutical Company Limited is a Japan-based company mainly engaged in the pharmaceutical business. The Company is engaged in the research, development, manufacture and sale of pharmaceutical products, General medical products, quasi drugs and healthcare products in Japan and overseas. The Company's research and development functions are concentrated in four areas of oncology (cancer), digestive system diseases, rare diseases and neurology (neuropsychiatric diseases), as well as two business units of plasma fractionation products and vaccines. The Company is engaged in the improvement of pipelines at research and development centers located mainly in Japan and the United States.

Contact details

Address:
4F, 2-1-1, Nihombashihon-cho
CHUO-KU
103-8668
Japan
Telephone:
+81 (3) 32782111
Website:
https://www.takeda.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
TAK
ISIN:
US8740602052
Market cap:
$42.06 billion
Shares in issue:
1.57 billion
Sector:
Pharmaceuticals
Exchange:
New York Stock Exchange
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Christophe Weber
    President, Chief Executive Officer, Representative Director
  • Milano Furuta
    Chief Financial Officer, Director
  • Costa Saroukos
    Chief Financial Officer, Director
  • Andrew Plump
    President of Research & Development, Vice President of Subsidiary, Director

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.